Lasmiditan Succinate Patent Expiration
Lasmiditan Succinate is Used for managing acute migraine attacks. It was first introduced by Eli Lilly And Co
Lasmiditan Succinate Patents
Given below is the list of patents protecting Lasmiditan Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Reyvow | US12071423 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | Jul 06, 2040 | Eli Lilly And Co |
| Reyvow | US11053214 | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists | Dec 05, 2037 | Eli Lilly And Co |
| Reyvow | US7423050 | Pyridinoylpiperidines as 5-HT1F agonists | Feb 17, 2028 | Eli Lilly And Co |
| Reyvow | US8748459 | Pyridinoylpiperidines as 5-HT1F agonists |
Mar 27, 2023
(Expired) | Eli Lilly And Co |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lasmiditan Succinate's patents.
Latest Legal Activities on Lasmiditan Succinate's Patents
Given below is the list recent legal activities going on the following patents of Lasmiditan Succinate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate Critical | 11 Aug, 2023 | US7423050 |
| Electronic Review Critical | 16 May, 2023 | US7423050 |
| FDA Final Eligibility Letter Critical | 26 Apr, 2023 | US7423050 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED Critical | 19 Apr, 2023 | US7423050 |
| Interim Patent Term Extension Granted Critical | 27 Mar, 2023 | US7423050 |
| Terminal Disclaimer Filed Critical | 27 Mar, 2023 | US7423050 |
| PTE Interim Patent Extension filed Critical | 23 Mar, 2023 | US7423050 |
| transaction for FDA Determination of Regulatory Review Period | 13 Sep, 2022 | US7423050 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Sep, 2022 | US7423050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Nov, 2021 | US8748459 |
Lasmiditan Succinate's Family Patents
